Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial
Randall J. Bateman, Yan Li, Eric M. McDade, Jorge J. Llibre-Guerra, David B. Clifford, Alireza Atri, Susan L. Mills, Anna M. Santacruz, Guoqiao Wang, Charlene Supnet, Tammie L. S. Benzinger, Brian A. Gordon, Laura Ibanez, Gregory Klein, Monika Baudler, Rachelle S. Doody, Paul Delmar, Geoffrey A. Kerchner, Tobias Bittner, Jakub Wojtowicz, Azad Bonni, Paulo Fontoura, Carsten Hofmann, Luka Kulic, Jason Hassenstab, Andrew J. Aschenbrenner, Richard J. Perrin, Carlos Cruchaga, Alan E. Renton, Chengjie Xiong, Alison A. Goate, John C. Morris, David M. Holtzman, B. Joy Snider, Catherine Mummery, William S. Brooks, David Wallon, Sarah B. Berman, Erik Roberson, Colin L. Masters, Douglas R. Galasko, Suman Jayadev, Rachel Sanchez-Valle, Jeremie Pariente, Justin Kinsella, Christopher H. van Dyck, Serge Gauthier, Ging-Yuek Robin Hsiung, Mario Masellis, Bruno Dubois, Lawrence S. Honig, Clifford R. Jack, Alisha Daniels, David Aguillón, Ricardo Allegri, Jasmeer Chhatwal, Gregory Day, Nick Fox, Edward Huey, Takeshi Ikeuchi, Mathias Jucker, Jae-Hong Lee, Allan I. Levey, Johannes Levin, Francisco Lopera, JeeHoon Roh, Pedro Rosa-Neto, Peter R. Schofield, Dominantly Inherited Alzheimer’s Disease-Trials Unit
medRxiv 2024.10.29.24316289; doi: https://doi.org/10.1101/2024.10.29.24316289
